<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03910296</url>
  </required_header>
  <id_info>
    <org_study_id>19-035</org_study_id>
    <nct_id>NCT03910296</nct_id>
  </id_info>
  <brief_title>Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain</brief_title>
  <official_title>Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to develop a psychological treatment for patients with
      cancer, focused on the psychological symptoms they experience during opioid therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Pilot Study, which is the first time investigators are examining
      this psychological intervention in patients with advanced disease, on opioid therapy. This
      study is being conducted to develop a psychological intervention designed specifically for
      individuals with cancer. The purpose of this study is to determine how practical this
      intervention is, to determine patient satisfaction, and test the study procedures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2019</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study feasibility</measure>
    <time_frame>2 years</time_frame>
    <description>Defined by participants' completion of 80% of measures</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intervention acceptability</measure>
    <time_frame>2 years</time_frame>
    <description>Defined by participant responses on the semi-structured qualitative interviews, upon treatment completion.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Acceptance &amp; Commitment Therapy</arm_group_label>
    <description>Acceptance &amp; Commitment Therapy (ACT) use acceptance, mindfulness, commitment, and behavior change strategies to increase psychological flexibility.
Each subject will participate for 6 sessions of Acceptance &amp; Commitment Therapy (ACT).
ACT trains patients to reframe their unpleasant, negative, private events while encouraging personal values.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Acceptance &amp; Commitment Therapy</intervention_name>
    <description>ACT is a unique, third-wave therapy that uses metaphors and experiential exercises to encourage contact with previously avoided thoughts, feelings, and behaviors.</description>
    <arm_group_label>Acceptance &amp; Commitment Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All potentially eligible patients will be identified through the DFCI ambulatory palliative
        care clinics.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  must be at least 18 years of age

          -  speak and comprehend English sufficiently to be able to complete the study procedures
             and participate in psychotherapy in English

          -  have been diagnosed with cancer

          -  have an estimated survival time ≥6 months (as approximated by palliative care clinic
             staff)

          -  score ≥4 on the Opioid Risk Tool (Webster &amp; Webster, 2005) with psychosocial distress
             as one of the positive items.

        Exclusion Criteria:

          -  bipolar disorder

          -  psychotic disorders

          -  borderline personality disorder

          -  have an estimated survival time ≤6 months (as approximated by clinic staff).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miryam Yusufov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miryam Yusufov, PhD</last_name>
    <phone>617-582-7618</phone>
    <email>miryam_yusufov@dfci.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miryam Yusufov, PhD</last_name>
      <phone>617-582-7618</phone>
      <email>miryam_yusufov@dfci.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Miryam Yusufov, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>April 8, 2019</study_first_submitted>
  <study_first_submitted_qc>April 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>MiryamYusufov</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cancer</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>BCH - Contact the Technology &amp; Innovation Development Office at www.childrensinnovations.org or email TIDO@childrens.harvard.edu BIDMC - Contact the Beth Israel Deaconess Medical Center Technology Ventures Office at tvo@bidmc.harvard.edu BWH - Contact the Partners Innovations team at http://www.partners.org/innovation DFCI - Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu MGH - Contact the Partners Innovations team at http://www.partners.org/innovation</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

